Trials / Conditions / Recurrent Uterine Corpus Sarcoma

Recurrent Uterine Corpus Sarcoma

12 registered clinical trials studyying Recurrent Uterine Corpus Sarcoma.

Status	Trial	Sponsor	Phase
Completed	Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus NCT01637961	National Cancer Institute (NCI)	Phase 2
Completed	Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01548482	National Cancer Institute (NCI)	Phase 1
Completed	Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer NCT01247571	National Cancer Institute (NCI)	Phase 2
Completed	Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated NCT01220609	National Cancer Institute (NCI)	Phase 2
Completed	Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer NCT01168232	National Cancer Institute (NCI)	Phase 2
Completed	Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Pa NCT01098630	Gynecologic Oncology Group	—
Completed	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recu NCT01012297	National Cancer Institute (NCI)	Phase 3
Completed	Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer NCT00114218	Gynecologic Oncology Group	Phase 2
Completed	Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Can NCT00031629	Gynecologic Oncology Group	Phase 2
Completed	Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus NCT00025506	National Cancer Institute (NCI)	Phase 2
Completed	Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus NCT00025220	National Cancer Institute (NCI)	Phase 2